SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shree Ganesh Remed. - Quaterly Results

08 Nov 2025 Evaluate
A decrease in the sales to Rs. 303.15 millions was observed for the quarter ended September 2025. The sales stood at Rs. 323.32 millions during the similar quarter previous year.The Company's Net profit for the September 2025 quarter have declined marginally to Rs. 49.56  millions as against Rs. 64.16 millions reported during the corresponding quarter ended.Operating profit for the quarter ended September 2025 decreased to 103.09 millions as compared to 114.98 millions of corresponding quarter ended September 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202509 202409 % Var 202509 202409 % Var 202503 202403 % Var
Sales 303.15 323.32 -6.24 549.83 571.12 -3.73 1085.96 1258.95 -13.74
Other Income 6.90 1.88 267.02 13.52 7.33 84.45 37.30 30.71 21.46
PBIDT 103.09 114.98 -10.34 182.68 201.67 -9.42 429.42 448.77 -4.31
Interest 10.10 4.28 135.98 19.50 7.44 162.10 20.77 5.98 247.32
PBDT 92.99 110.70 -16.00 163.18 194.23 -15.99 408.65 442.79 -7.71
Depreciation 25.87 24.24 6.72 50.07 44.42 12.72 95.67 61.10 56.58
PBT 67.12 86.46 -22.37 113.11 149.81 -24.50 312.98 381.69 -18.00
TAX 17.56 22.30 -21.26 29.05 39.13 -25.76 81.99 100.52 -18.43
Deferred Tax 2.17 -0.14 -1650.00 3.47 0.14 2378.57 -0.45 6.74 -106.68
PAT 49.56 64.16 -22.76 84.06 110.68 -24.05 230.99 281.17 -17.85
Equity 128.38 128.43 -0.04 128.38 128.43 -0.04 128.38 125.83 2.03
PBIDTM(%) 34.01 35.56 -4.38 33.22 35.31 -5.91 39.54 35.65 10.93

Shree Ganesh Remed. Share Price

486.65 12.35 (2.60%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×